ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has announced a prospectus for the potential offering of up to $100 million in mixed securities, which may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The securities may be offered in various combinations and in one or more offerings. The securities may be convertible, exercisable, or exchangeable for other securities, and the offerings may be conducted through underwriters, dealers, agents, or directly to purchasers. The company has conducted reverse-stock-splits on December 4, 2023, and April 25, 2024, with ratios of 1-for-35 and 1-for-10, respectively, and all share and price information has been adjusted accordingly. The company's common stock is listed on The Nasdaq Stock Market LLC under the...Show More

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has announced a prospectus for the potential offering of up to $100 million in mixed securities, which may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The securities may be offered in various combinations and in one or more offerings. The securities may be convertible, exercisable, or exchangeable for other securities, and the offerings may be conducted through underwriters, dealers, agents, or directly to purchasers. The company has conducted reverse-stock-splits on December 4, 2023, and April 25, 2024, with ratios of 1-for-35 and 1-for-10, respectively, and all share and price information has been adjusted accordingly. The company's common stock is listed on The Nasdaq Stock Market LLC under the symbol 'ZVSA.' As of August 30, 2024, the last reported sale price of ZyVersa's common stock was $2.77 per share. The company has not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus. The date of the prospectus is September 9, 2024.